A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors
| मुख्य लेखकों: | , , , , , , , , , , , |
|---|---|
| स्वरूप: | Journal article |
| प्रकाशित: |
2007
|
| _version_ | 1826272890916438016 |
|---|---|
| author | Nathan, P Judson, I Padhani, A Harris, A Sinha, R Jane, B Smythe, J Fisher, N Taylor, J Collins, D Connors, H Gordon, R |
| author_facet | Nathan, P Judson, I Padhani, A Harris, A Sinha, R Jane, B Smythe, J Fisher, N Taylor, J Collins, D Connors, H Gordon, R |
| author_sort | Nathan, P |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T22:19:43Z |
| format | Journal article |
| id | oxford-uuid:549d3172-72e0-405c-98db-75b4deb21468 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T22:19:43Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:549d3172-72e0-405c-98db-75b4deb214682022-03-26T16:39:01ZA phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumorsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:549d3172-72e0-405c-98db-75b4deb21468Symplectic Elements at Oxford2007Nathan, PJudson, IPadhani, AHarris, ASinha, RJane, BSmythe, JFisher, NTaylor, JCollins, DConnors, HGordon, R |
| spellingShingle | Nathan, P Judson, I Padhani, A Harris, A Sinha, R Jane, B Smythe, J Fisher, N Taylor, J Collins, D Connors, H Gordon, R A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors |
| title | A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors |
| title_full | A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors |
| title_fullStr | A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors |
| title_full_unstemmed | A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors |
| title_short | A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors |
| title_sort | phase i study of the safety tolerability and antitumor activity of escalating doses of combretastatin a4 phosphate ca4p given in combination with bevacizumab to subjects with advanced solid tumors |
| work_keys_str_mv | AT nathanp aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT judsoni aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT padhania aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT harrisa aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT sinhar aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT janeb aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT smythej aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT fishern aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT taylorj aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT collinsd aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT connorsh aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT gordonr aphaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT nathanp phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT judsoni phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT padhania phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT harrisa phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT sinhar phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT janeb phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT smythej phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT fishern phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT taylorj phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT collinsd phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT connorsh phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors AT gordonr phaseistudyofthesafetytolerabilityandantitumoractivityofescalatingdosesofcombretastatina4phosphateca4pgivenincombinationwithbevacizumabtosubjectswithadvancedsolidtumors |